

# Index

Tables, figures, and case studies are indicated by appending “t”, “f”, or “c” to the page number. Contents of tables are not indexed separately.

## A

absorption, distribution, metabolism and excretion (ADME)

gene therapy products, 466, 468  
preclinical testing, 302–303

accelerated assessment

additional pathways for, 538–539

ATMPs, 452, 453t

CAT request for human tissues, 480

CHMP recommendation for, 35

conditional authorisation, 475

EMA advice meetings, 44t

EMA initiatives, 101

for orphan designation products, 538

prepandemic influenza vaccines, 496

procedures for, 475

registration of medicinal products, 347

regulatory mechanisms for, 3–4

requests for, 283

*See also* PRIME (PRiority MEdicines)

*Active Implantable Medical Device Directive (AIMDD)*

repeal of, 184–185

transition from, 178

*See also* EU MDR and EU IVDR

active implantable/active medical devices

classification change for, 146

classification rules for, 191t

legal framework for, 165–170

MDR rules

medical device legislation and classification, 191t

active pharmaceutical ingredients (API)

EDQM inspection process, 369

in generic products, 377

Active Substance Master File (ASMF)

with combination products, 550

generic medicinal products, 384

IGDRP work on, 384

MA dossier quality section, 280

medicinal product registration, 350

acute/repeat dose toxicity studies, 303

Ad Hoc Expert Group

MAA review, 54

meeting of, 56

adaptive and alternative pathways

accelerated access initiatives by EMA, 295–296

eligibility for, 295, 297f, 346

HTA/EMA collaboration for, 88–89

legal framework for, 296–298

medicinal products, 296–298

for orphan designation products, 539

principles of, 296

procedural guidance for, 298

product eligibility for, 297f

*Addition of Vitamins and Minerals and of Other Substances to Food Regulation*, 504

Advanced Therapy Medicinal Products (ATMPs)

authorised in EU, 455t

borderline and criteria precluding from, 457–460

certification of, 460

characterisation and quality control, 462

classification of, 456–457, 457t, 477–478

classification procedures for, 456–460

GTMP, 461–462, 464–465, 466

legal framework, 480

MA procedures for, 480

pharmaceutical regulation evolution, 21–22

- preclinical development, 465–466
  - product characterisation, manufacturing and quality control of, 462–463
  - regulation, 451–470, 480
  - risk management for, 466–467
  - sCTMPs, 460–461, 462, 463–464, 465–466
  - subcategories of, 452–453
  - summary, 467–468
  - supply without MA grant, 455–456
  - TEPs, 461, 463, 465, 466
  - Adverse Drug Reactions (ADRs)/reporting
    - for biosimilar medicinal products, 401
    - defined, 313
    - Eudra Vigilance databases, 318, 401
    - from healthcare professionals, 438
    - human blood or plasma products, 525
    - nonprescription medicinal products, 409
    - for paediatric product development, 100
    - PRAC activities for, 387
    - requirements of Member States, 386–387
    - See also* pharmacovigilance
  - advertising and promotion, 103–114
    - abbreviated ads as reminders, 106
    - comparative advertisements, 110
    - contents for HCPs, 105–106
    - EFPIA goals and code, 104–105
    - enforcement by competent authorities, 120
    - to general public, 108
    - general public content, 107–108
    - generic medicinal products, 389
    - HCPs, 105–106
    - to healthcare professionals, 105
    - healthcare professionals (HCPs), 105, 106–107
    - Internet media, 109
    - jurisdictions for, 111–112
    - market surveillance, 110–111
    - medical devices, 112
    - nonauthorised products, 109–110
    - nonprescription medicinal products, 408–409
    - off-label information, 109–110
    - OTCs, 108
    - preapproval of material, 111–112
    - press releases, 108–109
    - regulatory framework, 103–104
    - regulatory strategy for, 138
    - sales representatives/sample distribution, 105–106
    - scientific service by MAA, 111
    - self-regulation, 104–105
  - affiliated countries and competent authorities, 161–163t
  - American Association of Tissue Banks (AATB), 473
  - Anatomic, Therapeutic, Chemical Classification (ATC) code, 282
  - animal models
    - nonclinical testing, 235c
    - pharmacodynamic testing, 395–396
    - preclinical device testing, 235c
    - tissue-engineered product, 495
  - Annual Safety Reports (ASRs), 311
  - authorisation procedures for medicinal products
    - Centralised and Mutual Recognition Procedures for, 278–279
    - Centralised Procedure, 281–285
    - Decentralised Procedure, 287–289, 290t
    - eCTD format and acceptability, 281
    - legal framework for MAA, 278–279
    - MA dossier quality section, 280
    - MA system, 278–279
    - Mutual Recognition Procedure, 285–287
    - national authorizations, 289
    - Notice to Applicants (NTA)* for medicinal products, 278–279
    - referrals, 292, 293
  - Authorised Representatives, 216, 255–256, 255t
- B**
- Belgium
    - advertising preapproval, 111
    - BeNeLuxA, 23
  - bench testing for devices, 234–235c
  - bibliographic applications/well-established use, 291–292
  - biocompatibility testing
    - nonclinical studies, 234c, 235c
    - preclinical test plan, 229
    - requirements from standards and risk management, 230–231
    - in tissue-engineered products, 465
  - bioequivalence, 378, 380–381
  - Biologics Working Party (BWP), 21, 522
  - biosimilar medicinal products
    - administration route and dosage parameters, 397
    - authorised active substance in, 394
    - clinical comparability demonstration for, 396–397
    - comparability to reference product, 394–395
    - comparative development of, 399f
    - development processes for, 395f, 396f
    - effects of change to reference product, 399
    - GLPs for, 396
    - immunogenicity testing for, 397
    - MAA data package for, 400t
    - MAA submission for, 397–398
    - pharmaceutical regulation evolution, 22
    - pharmacovigilance and safety reporting, 400
    - postapproval lifecycle management, 399–400

- preclinical study program for, 395
  - registration of, 397–399
  - safety reporting for, 400–401
  - therapeutic interchangeability, 22, 399
  - timeline for development of, 397f
  - types of biological medicinal products, 393–394
  - urgent safety restrictions for, 400
  - biotechnology-derived products
    - accelerated assessment procedure, 415
    - centralised procedure for, 415–416
    - clinical information, 419
    - conditional authorisation, 415
    - development processes for, 394, 416
    - developmental pharmaceuticals, 416
    - exceptional circumstances application procedure, 415
    - GLP for preclinical testing, 418–419
    - MA maintenance, 416
    - manufacturing information for, 417
    - pathways to marketing authorisation, 413–414
    - pharmacovigilance and safety reporting, 419
    - postapproval lifecycle comparability, 419
    - postapproval variations, 419
    - registration procedures for, 414–415
    - release testing in Europe, 418
    - TSE and viral clearance data for, 417–418
  - Blood Products Working Party (BPWP), 522
  - borderline products classification, 200–201
  - Brexit. *See* United Kingdom (UK)
  - British Pharmacopoeia (BP)*
    - quality systems and inspectorate process, 373
- C**
- carcinogenicity studies, 303
  - CE Mark
    - compliance confirmation with, 155
    - countries requiring, 272
    - for IVDS, 213–214
  - central individual case study report (ICSR)
    - electronic submissions, 449
    - in PMSF, 440
    - processing center performance, 441
    - submission and processing requirements, 443, 445, 445f
  - centralised marketing authorisation
    - MAA review for, 53–60
    - medicinal products, 278–279
  - Centralised Procedure (CP)
    - advantages and disadvantages for biotechnology products, 415, 419
    - advantages/risk comparison for nonprescription medicines, 406t
    - application evaluation timetable for, 284t
  - ATMP MAA timetable, 481–483t
  - authorisation system, 20
  - biosimilar medicinal product registration, 397, 401
  - biosimilar medicinal products, 397
  - biotechnology-derived product marketing
    - authorisation, 407–408, 413
  - Brexit effects for UK, 10
  - combination products, 544
  - comparison of pathways for nonprescription products, 406f
  - DNA and therapeutic vaccines, 497
  - dossier assessment procedures, 354
  - dossier requirements, 433
  - eligibility request for generic medicinal products, 386
  - EMA committee evaluation of products, 7, 14
  - EMA presubmission guidance, 414
  - evaluation of products, 14
  - generic medicines, 379
  - human blood/plasma product registration, 523
  - human blood/plasma product renewal and pharmacovigilance, 525
  - Information and Work Sharing projects, 386
  - inspection process with, 366
  - labelling and package leaflet (PL), 388
  - MA issued under, 285
  - MAA evaluation by EMA, 2
  - MAA procedures, 281–283, 355f
  - medicinal product authorisation, 381
  - medicinal product authorisation procedures, 281–285
  - medicinal product clinical trials, 385
  - national competent authorities medicine
    - authorisation, 561
  - for nonprescription medications, 405
  - orphan medicinal products, 525
  - pan-European generic authorisation, 391
  - pan-European registration system, 19
  - postauthorisation assessment procedure, 426
  - prepandemic influenza vaccines, 496
  - prescription to nonprescription reclassification, 407–408
  - product criteria for use, 19, 287, 293, 414
  - product exclusivity under, 291
  - registration of medicinal products, 341, 344
  - regulatory dossier assessment, 354
  - regulatory information resources for, 554, 557, 574
  - scientific advice and parallel meeting for, 48
  - vaccine licensure, 492
  - variation assessment and notifications, 433–435
  - certificate of analysis, 369, 490

- Certificate(s) of Suitability (CEP)
  - for APIs, 380
  - EDQM issue of, 280, 352
  - GMP inspections, 367–369
  - registration of medicinal products, 352
  - significance of, 369–370
- Chemical Abstracts Service (CAS) number, 305
- Clinical Effectiveness (EFF) HTA model, 80
- clinical evaluation and clinical investigations
  - bench testing, 234c, 235c
  - CE Mark requirements, 238
  - Clinical Evaluation Report (CER), 238
  - clinical pathway review, 241
  - clinical strategy plan, 240
  - clinical trial essentials, 241
  - common mistakes in, 241–242
  - elements of device evaluation, 238–239
  - equivalence to existing device, 239
  - GCP and quality in, 241
  - objectives of clinical investigation, 239
  - performing clinical investigation, 240–241
  - planning the evaluation, 239–240
  - report required, 238
- Clinical Evaluation Report (CER), 238–240
- Clinical Investigation Protocol (CIP), 171, 241
- clinical investigations vs clinical trials
  - MDD, EU MDR definitions of, 116
  - See also specific products*
- Clinical Trial Application (CTA)
  - EU laws and regulations, 39
  - vaccines, 490
- clinical trial authorisation process
  - application to national competent authority, 320
  - Ethics Committee evaluation and Member State competent authority, 319–320
  - Ethics Committee opinion application, 320
  - GMO-based products, 463, 497–498
- Clinical Trials Directive (CTD)*, 310–312
  - amendment of in-progress clinical trial, 323
  - Annual Safety Reports (ASR) requirements of, 312
  - application to IMPS, 315–317
  - clinical trial end declaration, 323–324
  - CTA process and authorisation process, 319–323
  - declaring end of clinical trial, 323–324
  - ECTR significant changes from, 314–315t
  - EudraCT changes, 318–319
  - EudraPharm function, 319
  - objectives and transition to *ECTR*, 310, 312
  - serious adverse reaction (SAR) reporting, 313
- Clinical Trials Facilitation Group (CTFG), 313
- clinical trials for medicinal products, 309–340
  - amendment notifications, 320–323
  - biological product guidance, 490
  - clinical trial application scientific assessment, 327f
  - clinical trial authorisation procedure, 326f
  - clinical trial regulatory telematics structure transitions, 317–318
  - DSUR contents, 334t
  - ECTR* and *Clinical Trials Directive* definitions, 316–317t
  - ECTR* implementation
    - clinical trial application process, 324
    - clinical trial authorisation, 324
    - CTA dossier contents, 329f
  - EU Clinical Trials Register (EUCTR), 319
  - EU Telematics, 317–318
  - Part II CTA assessment, 328f
  - serious adverse event reporting, 332f
- Coding Directive*, 485
- combination products, 543–552
  - borderline products, 545
  - conformity assessment requirements, 549
  - determination of registration pathway, 544
  - directives and guidance documents, 547–548
  - heparin and AIMD, 551c
  - IVDs and CDx, 550
  - labelling requirements, 551
  - medicinal product/device delineation, 543–544
  - pharmaceutical consultation procedure, 549–550
  - postmarket surveillance requirements, 551
  - product classification by PMOA, 544–547
  - quality system requirements, 550–551
  - regulatory classification determination, 548
  - set for local anaesthesia with lidocaine, 551–552c
  - sunblock cream/embedded barrier for vitiligo, 552c
  - in vitro* fertilisation/transplant organs or tissue, 551c
- combined ATMPs (cATMPs), 452, 456, 467
- Committee for Advanced Therapies (CAT)
  - ATMP* classification and certification by, 457t, 460, 477, 533
  - ATMP* Regulation and, 453–457
  - combination products, 550, 557
  - EMA responsibility for, 164
  - feedback during MA review, 54, 55f
  - MAA evaluation by, 480
  - MAA review, 53–54, 54t
  - PRAC advise to, 56
  - PRIME rapporteur appointment from, 36–37
  - rapporteur appointment from, 282, 430
  - representation in, 54
  - responsibilities of, 4, 8, 54t

- Committee for Medicinal Products for Human Use (CHMP)
  - ATMP* marketing authorisation, 48o
  - conditional marketing authorisation grant, 35
  - GCP adoption by, 330, 445
  - human blood or plasma product regulation, 522, 531
  - inspection requests from, 366
  - MAA review, 53–54, 54t
  - meeting preparation timeline, 57f
  - PDCO appointments, 95
  - PRAC recommendation endorsements, 119
  - responsibilities of, 7
- Committee for Medicinal Products for Veterinary Use (CVMP), 8, 366, 555, 557
- Committee for Orphan Medicinal Products (COMP), 343
  - orphan designation request review, 38
  - rare disease designation review, 53o
  - responsibilities of, 8, 343, 532
  - scientific advice from, 37, 48
- Common European Submission Portal (CESP), 323–324
- Common Specification (CS): GSPRs verifications, 225
- Common Technical Document (CTD)
  - biotechnology-derived product pharmaceuticals, 416–417
  - eCTD envelope, 351–352, 352t
  - eCTD format and acceptability for medicinal products, 281
  - MAA EU format and content, 280–281
  - medicinal product registration, 351–352, 351t
  - for vaccines, 490
- Common Technical Specifications (CTS) for IVDs, 214
- Communication and Tracking System (CTS) data base, 288–289
- community interest referral, 293
- competent authorities. *See* national competent authorities
- Competent Authorities for Medical Devices (CAMD), 116, 164
- Complete/Full and Independent application, 289
- compliance and postmarket surveillance (devices)
  - clinical followup for AIMDs and MDs, 260–261
  - Eudamed, 266–267
  - feedback mechanisms for, 257–258
  - Field Safety Corrective Action (FSCA), 258
  - follow-up investigation, 264–265
  - FSCAs and FSNs, 265
  - GPSD*, *MDD*, and *EU MDR* relationship, 258–259
  - incidents and criteria for reporting, 262–264
  - medical device global vigilance, 266
  - PMS vs vigilance, 266–267
  - postmarket surveillance procedures, 259
  - risk management in device industry, 260
  - surveillance and control provisions, 267–268
  - trend reporting, 265
- Concerned Member States (CMS)
  - application review timeline in, 322
  - authorisation of clinical trials under *ECTR*, 324–325
  - clinical trial acceptability, 324–325
  - clinical trial management and notifications, 328
  - clinical trial safety procedures, 323
  - clinical trials for medicinal products, 311
  - communications with Reference Member State, 355–356
  - decentralised procedure applications, 345
  - decentralised procedure referral, 293
  - decentralised procedures, 288, 355–356
  - dossier validation in, 354
  - DSUR submission, 333
  - IMPD cross-referencing, 330
  - inspection report submission by sponsor, 330
  - manufacture and importation, 388
  - MRP, 356–357
  - Mutual Recognition Procedure phase 2 timeline, 286
  - national law application in, 337
  - RMS evaluation for MA, 19
  - scientific advice for IMPs, 324
  - scientific advice from competent authority, 322
  - sponsor selection of, 345
  - vigilance procedures in, 478
- conditional authorisation
  - accelerated assessment, 475
  - biotechnology-derived products, 415
  - by CHMP, 35
  - for orphan designation products, 538
  - registration of medicinal products, 346
- conformity assessment
  - AIMDD* documentation, 246
  - AIMDD* procedure, 250f
  - Authorised Representatives, 216, 255–256, 255t
  - CE marking process, 244–245
  - Class I device, self-declaration/self-certification, 250f
  - Class IIa procedure, 249f
  - Class III device options, 248f
  - Class IIIb procedures, 249f
  - conformity assessment in, 136
  - documentation for, 247
  - EC-type examination, 252, 254t
  - full quality assurance system, 253, 254t
  - high-risk IVD procedure, 253f
  - internal production control, 252, 254t
  - IVD procedure, 251f



*IVDD* Annex II list b procedure, 252f  
*IVDD* documentation, 247t  
 for IVDS, 216  
*MDD* conformity assessment documentation, 247t  
 Notified Bodies in, 255  
 procedures for, 246t  
 product quality assurance, 253, 254t  
 product risk class and, 245, 248, 251–252  
 product verification, 253, 254t  
 production quality assurance, 252–253, 254t  
 quality system requirements, 253, 255  
 self-testing IVD procedure, 251f  
 Cost and Economic Evaluation (ECO), 80  
 cost-based pricing (CbP model), 63–64  
 custom-made devices  
     Essential Requirements for, 171  
     *EU MDR* and *EU IVDR*, 170–171  
     medical device legal system, 165–171

## D

Danish Centre for HTA (DACEHTA), 78  
 Danish *Promotion Code*, 106  
 Decentralised Procedure (DCP)  
     applications to other Member States, 286  
     ATC code and, 282  
     biosimilar medicinal product registration, 397  
     biotechnology-derived product marketing authorisation, 413  
     CMDh, 8, 10  
     EU regulatory bodies for, 341  
     flow chart for, 290t  
     generic medicinal products, 381, 382  
     human blood/plasma postmarket requirements, 525  
     human blood/plasma product registration, 523  
     Information and Work Sharing projects, 386  
     initial MAA, 356f  
     market access mechanism, 19, 279, 285, 287–289  
     medicinal product authorisation procedures, 287–289  
     medicinal product registration, 344–345, 355–356  
     nonprescription medicinal products, 405  
     pathways for nonprescription products, 406f  
     postauthorisation requirements for pharmaceuticals, 424  
     referrals, 293  
     regulatory dossier assessment, 355–356  
     regulatory information resources for, 554  
     variation assessment and notifications, 431, 433–434

Declaration of Conformity (DoC)  
     authorised representative signature, 187  
     CE Mark for conformity, 155  
     Essential Requirements for, 213  
     under *EU IVDR*, 216  
     for placing on the market, 170  
     responsible person for regulatory compliance, 145  
     *See also* conformity assessment  
*Declaration of Helsinki*, 311, 390  
 delegated act definition, 366  
 Description and Technical Characteristic of Technology (TEC) HTA model, 80  
 Design Traceability Matrix, 231  
 Development International Birth Date (DIBD), 333  
 Development Safety Update Report (DSUR)  
     contents of, 334t  
     EVCTM for submission, 335  
     format for, 443, 444t  
     ICH guideline for, 313, 332–333  
     ICH replacement for annual report, 312  
 Directive defined, 184, 366  
 Directorate- General for Health and Consumers (DG SANCO), 522  
 Directorate-General for Health and Food Safety (DG SANTE), 522, 560  
 divergent decision referral, 293  
 dossier. *See* regulatory dossier  
 Draft Assessment Report (DAR), 355  
 drug and biologic regulatory pathways  
     MAA, 32  
     product development, 31–32  
 drug product process validation scheme, 351–352  
 drug-device combination products (DDCs)  
     classification, 193–194  
 Drug-Eluting Stent (DES) and medicinal substance, 234–235c

## E

electrical magnetic disturbance testing, 233  
 electrical safety, 233  
 Electrotechnical Commission (CENELEC), 225  
 EMA meeting preparation, MAA review  
     CHMP meeting preparation timeline, 57f  
     core briefing materials for, 57–58  
     early preparation for, 57  
     face-to-face meetings, 54–56  
     Q&A preparation, 58  
     rehearsals for, 59  
     rehearsals in Amsterdam, 59  
     representation and feedback from, 55f  
     Scientific committee role in, 53  
     scripting/developing core presentation, 58

- slide development and management, 58–59
- Standard Assessment Review Timeline, 55f
- steps for preparation, 56–57
- understand committee members, 57
- written briefing document, 58
- EMA meetings
  - advice meetings, 43–44t
  - communications for MAA, 41–52
  - general preparation for, 47–48
  - for MAA, 41–52
  - MAA procedural steps and, 42–47
  - during MAA review, 53–60
  - MAA review, 53–60
  - scientific advice review, 48
  - steps required for, 45t
  - timelines for, 46t
  - See also specific meeting types*
- enforcement
  - CE marking errors, 117
  - Eudamed communications, 118
  - medicinal product advertising and promotion, 119–120
  - medicinal product GMP compliance, 119
  - medicinal product pharmacovigilance, 119
  - medicinal products recalls, 119
  - notified bodies, 118
  - Safeguard Clause, 117
- Enpr-EMA, 101, 559t
- Essential Requirements (ER)
  - clinical investigation vs clinical evaluation, 238–239
  - compared to GSPRs, 230
  - conformity assessment for, 187
  - consensus standards definition by, 225
  - custom-made devices, 171
  - GHRF Essential Principles concept, 222–224
  - harmonised technical standards for, 177
  - intended purpose and, 167
  - for IVD manufacturer processes, 211
  - legal documents, 18
  - legislative harmonisation and compliance, 155, 213–214
  - manufacturer GSPR demonstration, 238
  - safety and performance vs technical documentation, 23–24
- Ethical Analysis (ETH) HTA model, 80–81
- Ethics Committees (ECs)
  - application for opinion on clinical trial, 320
  - contents of application to, 321t
- EU Clinical Trials Register (EUCTR), 319
- EU In Vitro Diagnostic Medical Devices Regulation (EU IVDR)*, 138
- EU laws and regulations
  - basic legislation for, 14
  - Clinical Trials Regulation (536/2014)*, 39
  - codification/clarification of *pharmaceutical directives*, 19
  - CTA, 38–39
  - current regulation evolution, 17–19
  - Directive 2001/83/EC, 165, 184
  - Directive 2004/27/EC, 165
  - economic issues, 16–17
  - falsification and counterfeiting, 17
  - General Data Protection Regulation (GDPR)*, 138
  - information availability and transparency, 16
  - IVDD*, 26
  - medical device regulation evolution, 23–24
  - medical product regulation development, 14–15
  - orphan medicinal products (OMPs), 38
  - paediatric development programs, 38
  - Paediatric Regulation*, 121
  - patient advocacy and involvement, 16
  - pharmaceuticals regulation, 20
  - PRIME, 36–37
  - product innovation, 15–16
  - scientific advice and protocol assistance, 37–38
  - traditional herbal medicinal products, 23
  - unsafe product consequences, 15
- EU MDR and EU IVDR*
  - ATMPs, 480–484
  - authorised representative, 173
  - authorised representative agreement contract forms, 179
  - classification and conformity assessment, 146
  - clinical evidence, trials, and regulatory compliance, 144–145
  - clinical investigation devices, 171
  - Commission recommendation, 174, 174t
  - custom-made devices, 170–171
  - delegated and implementing acts, 148
  - EC working groups, 165, 166–167t
  - Essential Requirements vs GSPRs, 238
  - governance structure, 147–148, 147f, 176f
  - healthcare establishments, 164
  - human tissues, cells and derivatives, 484
  - implementation of MAID goods package, 142–143
  - implications of, 148–149
  - importers and distributors, 164
  - improved elements, 173–174
  - industry representation/trade associations, 165, 167t
  - institutional cooperation and consensus building, 164–165
  - interpretation of device law
    - Commission as an arbitrator, 177
    - Commission guidance, 175–176
    - courts, 174
    - guidance from Member States, 177

- guidance from other sources, 177
- key directives, 165
- legal system evolution, 178
- manufacturer, 171–173
- manufacturers and authorised representatives, 164
- market access mechanism, 144
- MDD* and *EU MDR* device definitions, 168t
- MEDDEV guidance documents, 172–173t
- medical devices and active implantable medical devices, 142, 165–170
- national enforcement, 177–178
- NBOG Best Practice Guide, 175t
- notified bodies changes with, 144
- overview, 180
- own-brand labelling and reprocessing, 146–147
- postmarket surveillance and vigilance, 145–146
- product liability, 178–179
- proposed *IVDR* classification rules, 145f
- scope of device directives*, 165
- significance of technical standards, 177
- stakeholders, 159
- supply chain controls, 142f
- supply chain vigilance obligations, 179–180
- timeline for adopting/transitional regime, 148
- traceability, 143–144
- EU MDR* and *EU IVDR*
  - ISO 13485 in transition to, 255
  - QMS requirements and ISO 13485, 252–253
- EU Medical Devices Regulation (EU MDR)*, 480–481
- EU regulatory affairs
  - adaptive and alternative pathways, 295–300
  - advertising and promotion, 103–114
  - ATMP regulatory framework, 451–470
  - biosimilar medicinal products, 393–402
  - clinical evaluation and clinical investigations, 237–242
  - combination products, 543–552
  - drug and biologic regulatory pathways, 31–40
  - EMA and other regulatory bodies, 1–12
  - enforcement and competent authorities, 115–120
  - Falsified Medicines Directive (FMD)*, 121–134
  - food for special medical purposes, 511–518
  - food supplements, 501–510
  - generic medicinal products, 377–392
  - Health Technology Assessment (HTA), 77–92
  - history of regulations, 13–30
  - human blood or plasma products, 519–528
  - human tissue regulation, 471–488
  - MAA for biotechnology derived products, 413–422
  - Marketing Authorisation Application (MAA)
    - review, 53–60
  - Marketing Authorisation Application (MAA)
    - submissions, 41–52
  - medical device compliance/postmarket requirements, 257–269
  - medical device conformity assessment procedure, 243–256
  - medical device legislation and classification, 183–206
  - medical device national particularities, 271–276
  - medical device preclinical testing, 229–236
  - medical devices legal system, 151–182
  - medicinal product authorisation procedures, 277–294
  - medicinal product clinical trials, 309–339
  - medicinal product registration procedures, 341–362
  - new *MDR* and *IVDD* regulation, 141–150
  - nonprescription medicinal products, 403–412
  - orphan medicinal products (OMPs), 529–542
  - Paediatric Regulation*, 93–102
  - pharmaceutical postauthorisation requirements/compliance, 423–436
  - pharmaceutical quality systems and inspectorate process, 363–376
  - pharmacovigilance, 437–450
  - preclinical testing and GLP, 301–308
  - pricing and reimbursement, 61–76
  - regulatory information resources, 553–573
  - regulatory strategy, 135–140
  - safety and performance requirements/technical documentation, 221–228
  - vaccines, 489–500
  - in vitro* diagnostic devices (IVDDs), 207–220
- EU Tissue and Cell Directives (EUTCD)*, 471–473. *See also specific tissue and cell products*
- EU Treaty, 14
- Eudamed
  - competent authority communications, 118
  - market surveillance and vigilance, 267–268
- Eudra Vigilance databases, 318, 566
- EudraCT paediatric clinical trial records, 319
- EudraGMDP inspection information in, 369
- EudraVigilance Clinical Trial Module (EVCTM), 332, 335
- EudraVigilance medicinal product dictionary (xEVMPD), 440
- EudraVigilance Postauthorisation Module (EVPM), 493
- Eurasian Economic Union Member States, 374
- European Association of Tissue Banks (EATB), 473
- European Blood and Marrow Transplantation Group (EBMT), 473
- European Clinical Trial Database (EudraCT)
  - clinical trial databases, 38, 100
  - SUSAR reporting, 318



- European Clinical Trial Regulation (ECTR)*  
 adverse reactions in, 313  
 application to IMPS, 315–317  
 electronic reporting, 319  
 EU Clinical Trials Register (EUCTR), 317–318  
 EU Portal, 317  
 EU portal and database, and associated legacy systems, 311  
 EU Telematics Strategy and Implementation Roadmap, 317  
 EudraVigilance Clinical Trial Module (EVCTM), 317–318  
 evaluation for duplication, 318  
 implementation guidance documents, 312–313  
 Member States national laws and, 311  
 significant changes from *Clinical Trials Directive*, 314–315t
- European Commission (EC)  
 demonstration of GSPRs, 225  
 initiatives and models for pricing, 63–64  
*Notice to Applicants (NTA)* for medicinal products, 278–279  
 regulatory authorities, pharmaceutical quality, 365  
 Task Force for Relations with the United Kingdom (UKTF), 364, 366
- European community referral, 292
- European Directory for the Quality of Medicines (EDQM)  
 API assessment by, 380  
 CEP issued by, 280
- European Economic Area (EEA)  
 CE marking requirements, 272
- European Eye Banking Association (EEBA), 473
- European Federation of Pharmaceutical Industries and Associations (EFPIA)  
 CE marking requirements, 272  
 codes of conduct, 104–105  
 falsified medicines legislation, 123t  
 product distribution, 106–107, 111  
 regulatory information from, 564
- European Food Safety Authority (EFSA)  
 food supplement assessment by, 504–505  
 foods for special medical purposes, 513–514  
 scientific advice, 560
- European Generics Medicines Association (EGA), 379
- European Initiative for Paediatric Formulations (EuPFI), 100
- European Medicines Agency (EMA)  
 accelerated access initiatives, 295–300  
 early access initiatives, 88–89  
 EUnetHTA collaboration, 88–89, 88f  
 falsified medicine defined, 121  
 HTA parallel consultation, 88  
 marketing recommendation for medicinal products, 278–279  
 regulatory authorities, pharmaceutical quality, 365
- European Medicines Verification Organisation (EMVO), 131
- European Medicines Verification System (EMVS), 131
- European Network for HTA (EUnetHTA)  
 EMA collaboration, 88–89  
 HTA assessments, 78–88  
 MAA evaluation, 50, 65–67
- European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), 445–446
- European Pharmacopoeia (Ph. Eur.)*, 373
- European Public Assessment Report (EPAR), 283, 398–399
- European Society of Human Reproduction and Embryology (ESHRE), 473
- European Standardization Committee (CEN), 225
- European Transplant Coordinators Organisation, 473
- European Union (EU)  
 medical product regulatory bodies, 341–342  
 pricing and reimbursement, 61–76
- European Union Reference Dates (EURD)  
 active substances, 388  
 PSURs and PSUSAs scheduling, 360, 445
- exceptional circumstances  
 medicinal product registration, 346–347  
 for orphan designation products, 538–539
- expedited evaluation programs  
 ATMPs, 453t  
 decision tree for pathways, 454f  
*See also* Adaptive Pathways; alternative pathways; PRIME (PRiority MEDicines)
- External Reference Pricing (ERP)), 63, 64f. *See also* pricing and reimbursement
- F**
- facility requirements  
 medicinal requirements, 305
- Falsified Medicines Directive (FMD)*, 121–134  
 active substance GMP, 128  
 active substances and excipient definitions, 128t  
 combination therapies, 132  
 companion diagnostics, 132  
 defining, 122  
 detection and management goals of, 132  
 EMVS in, 131–132  
 examples of SFFC medicines, 126  
 falsified active substances in routes in supply

- chain, 125f
  - harmonisation of regulation, 124
  - implementation of, 124–125
  - implementation process for, 128–129
  - implications and challenges of, 129–131
  - initiatives relevant to, 129t
  - key term definitions, 124t
  - online logo requirements, 128f
  - problem scope, 122
  - stakeholder requirements, 124
  - stakeholder requirements under FMD, 127t
  - third countries requirements under, 125, 128, 129t
  - unique product identifiers and information flow, 131f
  - Field Safety Corrective Action (FSCA), 258
  - Field Safety Notices (FSNs), 265
  - first-in-human (FIH) trials guidance documents, 322
  - fixed-combination application, 292
  - follow-up referral, 292
  - Food and Drug Administration (FDA)
    - collaboration on paediatric products, 100
    - PSA for MAA/EMA meetings, 49
  - Food for Special Medical Purpose (FSMP) Regulation*, 512–513
  - food for special medical purposes (FSMPs)
    - communications and claims for, 516
    - competent authority notification of marketing, 516
    - compositional requirements for, 514–515
    - definition of, 513
    - food information and nutrition information, 515–516
    - FSMP critical concepts, 513–514
    - history of use, 511–512
    - legal framework for regulation, 512–514
    - reimbursement, 516
    - single-use plastics directive* for, 516
  - food supplements, 501–510
    - competent authority notification of marketing, 504
    - for food supplements, 505–507
    - harmonisation of, 507
    - health claims for, 505
    - labelling (information to consumers), 503–504
    - legal framework for regulation, 505–507, 512–513
    - quality requirements, 503
    - regulatory summary, 507–508
    - safety assessment of ingredients, 504
    - scope and definitions for regulation, 502–503
    - vitamin/mineral content for safety, 504
  - Food Supplements Directive (FSD)*, 502–504
  - foods for special medical purposes (FSMPs), 511–518
    - general principles of regulation, 512
    - for specific groups, 512
  - Foods for Specific Groups (FSG) Regulation*, 512–513, 516
  - France
    - advertising preapproval, 111
    - HTA in, 82t, 83t
    - HTA process in, 85f
    - pricing/reimbursement procedures, 68–69
    - pricing/reimbursement-HTA assessment
      - competent authorities, 68
    - Universal Health Coverage Act (CMU)*, 67
- G**
- gene therapy medicinal products (GTMPs)
    - clinical development, 466
    - decision tree for classification, 459f
    - intended use and manipulation criteria, 461
    - manufacturing process, 461–463
    - preclinical development, 464–465
  - General Electrical Safety Standard, 233
  - General Product Safety Directive (GPSD)*, 259
  - general safety and performance requirements (GSPRs)
    - applicable standards identification, 226
    - checklist for, 223–224t
    - device registration requirements, 216
    - historical foundations for, 221–222
    - IVDD* revision by *EU IVDR*, 216–217
    - manufacturer GSPR demonstration, 187, 238
    - predicate device requirement, 227
    - referencing applicable standards, 227
    - regulatory status of European standards, 225
    - requirements for, 222, 223
    - standards and common specifications use for, 225
    - technical documentation, 226–227
    - terminology change, 238
  - generic medicinal products, 377–392
    - advertising and promotion, 389
    - biosimilar applications, 383
    - biosimilar medicines, 380
    - comparison with innovator medicines and reference products, 377–378
    - compendial monographs for, 380
    - dossier requirements for, 383–386
    - electronic submission of information for, 390
    - GCP for, 390
    - GDP for, 389, 390
    - GLP for, 390
    - GMP for, 389–390
    - Good Pharmacovigilance Practices for, 386–387, 390

- GPMs for*, 379–380
- international regulations for, 386
- labelling and package leaflet, 388–389
- legal basis for generic application for MA, 381–383, 381t
- manufacture and importation for, 388
- postauthorisation surveillance of, 380
- PSURs for, 387–388
- RMP for, 387
- supervision and sanctions for, 390–391
- WHO definition of, 377
- wholesale distribution of, 389
- generic/Abridged application, 289–290
- genetically modified organisms (GMO)
  - GTMPs, 463
  - vector use in, 497–498
- genotoxicity studies, 303
- Germany
  - competent authorities for pricing// reimbursement and HTA, 69
  - Gesetzliche Krankenversicherung (GKV), 69
  - HTA in, 82t, 83t
  - HTA process in, 86f
  - medicinal product pricing under AMNOG, 70f
  - pricing/reimbursement procedures, 69–71
  - Safeguard Clause action (catgut), 267
- Global Harmonization Task Force (GHTF)
  - Essential Principles concept, 222
  - guidance document from, 240
  - IMDRF succession to, 266
  - IVD risk classification of IVDs, 212–213
  - risk-based device classification, 206
  - STED developed by, 226
  - See also* International Medical Device Regulators Forum
- Good Clinical Practice (GCP)
  - biological product guidance, 490
  - biosimilar clinical comparability demonstration for, 396–397
  - biotechnology-derived products, 416
  - clinical investigation of devices, 240–241
  - in drug life cycle, 364
  - for generic medicinal products, 390
  - legal framework and, 370–371
- Good Distribution Practice (GDP)
  - in drug life cycle, 364
  - for generic medicinal products, 389, 390
  - inspections for, 371
- Good Laboratory Practice (GLP)
  - ancillary quality system components, 306
  - for biosimilar medicinal products, 396
  - biotechnology-derived products, 416
  - definition, 301
  - in drug life cycle, 364
  - facility requirements, 305
  - for generic medicinal products, 390
  - inspections and compliance, 307
  - medicinal product requirements, 302
  - pharmacokinetic studies *in vitro*, 302–303
  - pharmacology safety studies, 302
  - preclinical studies required by, 302–303
  - products covered, 304
  - purpose and relevance guidance, 306–307
  - Quality Assurance programme, 305
  - regulations and guidelines for
    - toxicity studies, 302
  - reporting study results
    - content of study plan, 306
  - revisions for harmonisation, 307–308
  - SOPs for test facility, 306
  - study performance
    - study plan and content, 306
  - test and reference items
    - characterization, 305–306
    - receipt, handling, sampling and storage, 305
  - test facility organisation
    - management, 304
    - principal investigator, 305
    - study director, 304–305
  - test systems, 305
  - in vivo* feasibility and dose testing under, 303
- Good Manufacturing Practice (GMP)
  - biotechnology-derived products, 416
  - certificate, 119, 369, 390–391
  - in drug life cycle, 364
  - foods for special medical purposes, 512
  - for generic medicinal products, 389–390
  - for herbal medicines, 410
  - MAH compliance, 119
- Good Pharmacovigilance Practices (GVPs)
  - for biosimilar medicinal products, 400–401
  - in drug life cycle, 364
  - for generic medicinal products, 390
  - GVP overview and modules, 439–449, 439t
  - MA maintenance, 360
  - Module I: PV systems and quality systems, 439–440
  - Module II: PV system master file, 440
  - Module III: PV inspections, 440–442
  - Module IV: PV audits, 442–443
  - Module IX: signal management, 446–447
  - Module V: risk management systems (RMS), 443
  - Module VI: adverse reaction management/reporting, 443
  - Module VII: PSURs, 443–445
  - Module VIII: post authorisation safety studies, 445–446
  - Module X: additional monitoring, 447–448

- Module XV: safety communications, 448
- Module XVI: risk minimisation measures, 448–449
- nonprescription medicinal products, 409
- Guidance documents
  - European Commission Consensus Statements, 174t
  - European Commission documents, 174t, 175–176
  - MDCG, 185
  - MEDDEV Commission guidance, 172–173t
  - NBOG Best Practice Guide, 175t
  - TEAM-NB, 177
- H**
- harmonisation
  - EURD in, 388
  - of food supplements, 507
  - GLP regulations, 307–308
  - GSPR compliance demonstration, 225–226
  - medical device regulation, 24–25
  - of SmPC, 342, 345
  - standards for IVDs, 213–216
- Heads of Medicines Agencies (HMA), 311
- Health Claims (HCs)
  - food supplements, 505–506, 507
  - foods for special medical purposes, 513, 516
- health monitoring measures
  - actions against general threats to public health, 117
  - comparison with Safeguard Clause, 267–268, 267t
- Health Problem and Current use of Technology (CUR)
  - HTA model, 80
- Health Technology Assessment (HTA), 77–92
  - comparison in EU countries, 81–84, 83t
  - decision timeline, 87t, 88f
  - EMA and EUnetHTA collaboration, 88
  - harmonisation, 84–88
  - HTA in Member States, 82t
  - legal framework, 77–78
  - models used for: CUR, 80
  - models used for: ECO, 80
  - models used for: EFF, 80
  - models used for: ETH, 80–81
  - models used for: LEG, 81
  - models used for: ORG, 81
  - models used for: SAF, 80
  - models used for: SOC, 81
  - models used for: TEC, 80
  - organisation and structure in EU, 81–84
  - parallel advice for MAA, 49–51
  - pricing and reimbursement, 65–66
  - role in decision making, 84
  - role in product market, 78–80
- heated sleep apnea device, 234c
- herbal medicinal product MAA, 292
- human blood or plasma products, 519–528
  - batch-release requirements, 525
  - CHMP working groups, 522
  - Council of Europe publications on, 523
  - DG SANTE, 522
  - donation testing for, 523–524
  - guidelines and documents for, 523–524
  - legal framework, 522–523
  - marketing authorisation dossier for, 524–525
  - plasma master file, 525
  - plasma-derived medicinal products, 520–521, 521t
  - postmarketing pharmacovigilance for, 525
  - registration procedures for, 523
  - Single European Code structure, 476t
  - transition to new regulations, 525–526
  - TSE safety evaluation, 524
  - virus safety evaluation, 524
- Human Organ Transplantation Directive*, 485
- human tissue products, 471–487
  - ATMP classification, 477
  - classification of, 477–478
  - contiguous legislation, 484–485
  - distribution and import, 476
  - donation of, 474
  - donor selection and testing, 474–475, 475t
  - EUTCD requirements, 473–474
  - legislation on, 473–474
  - licensing and inspections, 478
  - MA authorisation for, 480
  - MA procedure for, 480
  - as medical device, 483
  - pharmacovigilance (PV), 477–478
  - processing and storage, 475–476
  - procurement, 474
  - quality system for establishment and responsible person, 478–479
  - regulation, 473, 480–484
  - regulatory framework for, 484t
  - responsible person qualifications/responsibilities, 479t
  - tissue establishments and banks, 478
  - traceability, 476–477
- hybrid applications, 291
- I**
- Identification of Medicinal Products (IDMP), 359
- immunogenicity data
  - advanced therapy medicinal products, 465
  - biosimilar medicinal product development, 395

- biotechnology-derived products, 417–419
- comparability exercise for biosimilars, 396–397, 398
- pre-licensing product testing, 349
- vaccines, 494, 496
- immunotoxicity studies, 303
- Impact on Clinical Research of European Legislation (ICREL), 310
- Importing Directive*, 485
- In Vitro Diagnostic Medical Devices Regulation (EU IVDR)*, 141–149, 189–200
- in vitro* diagnostic (IVD) medical device, 207–220
  - accessories, 210
  - classification disputes, 203
  - classification process, 201–203
  - companion diagnostic (CoDx), 211–212
  - device performance testing, 210
  - essential requirements for, 213
  - EU laws and regulations, 26
  - in-house developed, 211
  - IVD use, 209
  - IVDD* and *IVDR* classification rules, 204–205
  - IVDD* and *IVDR* scope, 208–209
  - IVDD* revision, 216–217
  - laboratory use products and IVD devices, 210t
  - manufacturer process, 211
  - medical device legislation and classification, 208–209
  - pan-European requirements, 207
  - regulations for safety, 217
  - research-only, 210–211
  - risk-based classification lists for, 212–213
  - specimen receptacles, 209–210
  - specimens examined, 209
- In Vitro Diagnostic Medical Devices Directive (IVDD)*, 184–185
- In Vitro Diagnostic Medical Devices Regulation (EU IVDR)*, 189, 544
- influenza vaccines, 494–496, 495f
- Information and Work Sharing projects, 386
- informed consent applications, 292
- in-house produced devices, 147
- innovator medicines (originator products), 378–379
- inspection process
  - in drug approval process, 367f
  - EudraGMDP database entries, 369
  - GLP regulations, 307
  - pharmaceuticals, 366–369
  - tissue establishment inspections, 478
- installation qualification (IQ), 306
- Instructions for Use (IFU)
  - contents for IVDs, 215
  - device evaluation and, 238
- international birth date (IBD), 333
- International Coalition of Medicines Regulatory Authorities (ICMRA), 374–375
- International Conference on Harmonisation (ICH)
  - coordination and cooperation enhancement, 117
  - Development Safety Update Report, 312
  - guidelines for biotechnology-derived products, 416–417
  - harmonisation of preclinical testing, 302
  - pharmaceutical quality systems, 365
  - PSUR format revision and scheduling, 445
- International Electrotechnical Commission (IEC)
  - medical device standards, 230–231, 233–234
  - standard use in EU, 164, 177
- International Federation of Pharmaceutical Manufacturers Association (IFPMA)
  - code of ethics, 103, 105, 107
  - promotional material approval, 111
- International Generic Drug Regulators Pilot (IGDRP), 386
- International Medical Device Regulators Forum (IMDRF)
  - consensus standards, 225–226
  - coordination and cooperation enhancement, 117
  - GHTF basis for, 266
  - inspection guidelines, 374
  - medical device global vigilance, 266
- International Medical Products Anti-Counterfeiting Taskforce (IMPACT), 122, 123t
- International Organization for Standardization (ISO)
  - consensus standards definition by, 225
  - standard harmonisation, 164, 561
  - use in preclinical testing, 230
  - See also specific standards*
- International Society of Pharmacoepidemiology (ISPE), 374, 445
- invasive devices: classification rules for (*MDR*), 190t
- Investigational Medicinal Product Dossier (IMPD)
  - biological product guidance, 490
  - content requirements for, 490
  - submission, 330–331
- investigational medicinal products (IMPs), 317
  - Clinical Trials Directive* definition of, 315
  - clinical trials for, 310
  - CTD information in dossier, 330
  - documentation requirements for, 490
  - DSURs for, 332
  - for FIH trials, 322
  - GMP requirements for, 331
  - manufacturing requirements for, 498
  - risk-benefit amendment notification, 322
  - SUSARs/DSURs for, 332
- ISO 13485
  - gap assessment for *EU MDR* and *EU IVDR*
  - transition, 255, 258



- harmonised quality system model, 214–215, 226
- production quality assurance model, 252–253
- QMS requirements, 215
- review of feedback, 259, 266, 268
- ISO 14971
  - FSCA warning methods, 265
  - harmonised standards for risk management, 214
  - postmarket surveillance and vigilance, 258
  - risk management requirements, 226, 266, 268
- Italian Farmaindustria Code, 106
- Italy
  - advertising preapproval, 111
  - competent authorities for pricing// reimbursement and HTA, 72
  - HTA in, 82t
  - pricing/reimbursement procedures, 72–73
  - Servizio Sanitario Nazionale (SSN)*, 72
- J**
- Joint Action on Market Surveillance (JAMS), 3, 116
- Joint Immediate Action Plan, 118
- L**
- labelling requirements
  - combination products, 551
  - food for special medical purposes (FSMPs), 515–516
  - for food for special medical purposes (FSMPs), 516
  - food supplements, 503–504
  - language for IVDs, 215–216
- Legal Aspects (LEG) HTA model, 81
- legal framework/legislation
  - for adaptive and alternative pathways, 296–298
  - Advanced Therapy Medicinal Products (ATMPs), 451–470, 480
  - ATMP Regulation*, 453–456
  - clinical trial improvements, 312f
  - clinical trials, 311
  - Directive defined, 184
  - for food supplements, 505–507
  - foods for special medical purposes and special groups, 512–514
  - herbal medicinal products, 409–410
  - human blood or plasma products, 522–523
  - human tissue products, 473–474
  - MAA, 32–34
  - mechanism for medicinal products for human use, 18–19
  - medical devices, 141–149, 150–182, 183–206
  - medical product, 18
  - Opinion, 184
  - orphan medicinal products, 530
  - pharmacovigilance (PV), 438–439
  - product legislation, 17–18
  - Recommendation, 184
  - Regulation defined, 184
- lifecycle of drugs
  - regulations in, 364f
  - research and development (R&D), 22–23
- local tolerance studies, 303
- M**
- Market Surveillance Operations Group (MSOG), 267
- Marketing Authorisation Application (MAA)
  - accelerated assessment for, 35
  - approval types, 34, 36t
  - for biosimilar medicinal products, 397–398
  - for biotechnology derived products, 292
  - clarification and discussion meetings, 54–55
  - communications to EMA, 41–52
  - dossier quality section, 280
  - EMA meetings during review, 53–60
  - EU format and content of, 280
  - human-veterinary variations, 20–21
  - legal basis and dossier requirements, 32–34
  - legal basis for generic application for MA, 381–383
  - medicinal product application types, 289–292, 290t, 291–292
  - for medicinal products, 279–284
  - PIP requirements, 94–95, 98–100
  - prior EMA meetings for, 41–52
  - procedural steps and EMA meetings, 42–47
  - procedure timelines for, 55f, 57f
  - procedures for, 34–35
  - scientific advice and protocol assistance, 37–38
  - Scientific Advice review, 54
  - Scientific committee role in review, 53, 54t
- Marketing Authorisation Holder (MAH)
  - advertising to general public, 108
  - advertising to healthcare professionals, 105
  - definition of, 279
  - EMVO, 119
  - GMP compliance, 119
  - MA maintenance, 359
  - obligations for medicinal products, 282, 284, 289
  - paediatric products, 99–100
  - PIP preparation, 94–95
  - product failure responsibility and liability, 342
  - renewal date agreement with Reference Member State, 424
  - responsibilities and obligations for medicinal products, 279–280
  - role in various application types, 292

- scientific service implementation, 111
- submission of information for generic products, 390
- worksharing, 359
- Marketing Authorisation (MA)
  - adaptive and alternative pathways, 295–300
  - food supplements, 504
  - for generic medicinal products, 391
  - human tissue products, 480
  - regulatory strategy for, 138
  - See also* Centralised Procedure; Mutual Recognition Procedure; National Procedure
- maximum tolerated dose (MTD), 302
- MEDDEV guidance documents
  - authorised representatives, 143
  - clinical evidence, trials, and regulatory compliance, 144, 146
  - revisions and updates, 118
- Medical Device Coordination Group (MDCG)
  - borderline combination products, 545
  - centralised governance, 159, 165
  - classification disputes, 203–205
  - CTS adoption by implementing act, 214
  - decisions on product qualification, 142
  - device classification determination, 142
  - enforcement and surveillance, 146–148, 159, 178
  - regulatory classification determination, 545, 548–549, 551
  - regulatory strategy development, 138
  - regulatory strategy information, 138
  - responsibilities of, 176–177
  - revised guidance from, 230
- Medical Devices Directive*
  - repeal of, 184–185
  - transition from, 178 (*see also* *EU MDR* and *EU IVDR*)
- medical device legal system
  - adaptive and alternative pathways, 298
  - clinical evaluation cycles, 159f
  - Commission as an arbitrator, 177
  - compliance verification, 155
  - conformity assessment for AIMDs, 157f
  - conformity assessment for IVD, 158f
  - conformity assessment procedures, 156f
  - custom-made devices, 165–171
  - development, 25–26
  - EC working groups and activities, 166–167t
  - EMA in, 164
  - enforcement, 117
  - enforcement and competent authorities, 117–118
  - Essential Requirements and technical standards, 177
  - essential requirements compliance, 155–159
  - industrial trade associations, 167t
  - legislative process, 150–152, 153f
  - manufacturer role in, 171
  - market surveillance, 117–118
  - MDD* and *EU MDR* device definitions, 168t
  - MEDDEV guidance documents, 171–172t
  - medical device laws, 165–170
  - national enforcement, 177–178
  - new approach regulatory philosophy, 153–154, 154t
  - new legislative framework (NLF), 157
  - regulation evolution and harmonisation, 23–25
  - See also* *EU MDR* and *EU IVDR*; *specific devices*
- medical device legislation and classification, 183–206
  - basic principles of application, 189–190
  - classification disputes, 203
  - classification matrix, 188t
  - comparison of *EU MDR* and *MDD* rules, 195–200t
  - EU MDR* and *MDD* rules, 200–201
  - human tissue/cell products with, 483
  - IVD classification process, 201–203, 202t
  - IVDD* and *IVDR* rule comparison, 204–205t
  - key concepts for classification, 191, 193
  - MDR* rules for invasive devices, 190t
  - MDR* rules: special, 192t
  - medical devices directives*, 184–185
  - medical devices definition and expansion of, 185–186
  - non-invasive devices rules, 189t
  - regulatory framework definitions, 184
  - requirements, 186–187
  - rule-based approach for, 187–189
  - transition to *EU MDR* and *EU IVDR*, 185
  - unclassified devices, 188
  - in vitro* diagnostic regulation, 189
- medical device national particularities
  - CE marking for, 271
  - directives and regulations for, 272t
  - EU outermost regions, 272t
  - language and labeling, 272–274
  - national languages, 274t
  - notification requirements, 274–275
  - translation requirements, 273t
  - See also* pricing and reimbursement
- Medical Device Vigilance System, 258, 261
- Medical Devices Coordination Group (MDCG), 159
- Medical Devices Regulation (EU MDR)*, 141–149
- Medicinal Product Directive (MPD)*, 18, 32, 506
- medicinal products for human use
  - adaptive and alternative pathways, 296–298
  - bibliographic applications/well-established use, 291–292
  - clinical trials for, 309–340
  - Complete/Full and Independent, 289

- decentralised procedures, 290t
  - enforcement, 119–120
  - enforcement and competent authorities, 118–120
  - factors affecting pricing, 62f
  - fixed-combination application, 292
  - generic/Abridged, 289–290
  - herbal medicinal products, 292
  - hybrid applications, 291
  - informed consent applications, 292
  - legislation in EU, 18–19
  - Marketing Authorisation Application, 289–292
  - mixed marketing, 292
  - medicinal products MAA applications
    - bibliographic applications/well-established use, 291–292
    - Complete/Full and Independent, 289
    - decentralised procedures, 290t
    - fixed-combination application, 292
    - generic/Abridged, 289–290
    - herbal medicinal products, 292
    - hybrid applications, 291
    - informed consent applications, 292
    - mixed marketing, 292
  - Medicines and Healthcare products Regulatory Agency (MHRA)
    - joint inspection programs, 372–373
  - Medicines for Europe, 379
  - Member States
    - clinical trial authorisation procedures in, 324
    - clinical trial safety procedures, 323
    - competent authorities and affiliated countries, 161–163t
    - competent authorities marketing guidelines, 278–279
    - enforcement by competent authorities, 115–120
    - EU MDR* and *ER IVDR* significance for, 159–164
    - GLP regulations in, 302
    - interim device actions under Safeguard Clause, 267
    - Marketing Authorisation Application in, 19
    - See also* Concerned Member States; national competent authorities
  - mixed marketing, 292
  - Mutual Acceptance of Data (MAD) system, 302, 370
  - Mutual Recognition Agreements (MRAs)
    - for generic product GMP inspections, 379–380
    - for inspections, 371
  - Mutual Recognition Facilitation Group (MRFG), 286
  - Mutual Recognition Procedure (MRP)
    - application format for, 281
    - authorisation of medicinal products, 285–287
    - biosimilar medicinal product registration, 381
    - biotechnology-derived product marketing authorisation, 413
    - comparison of pathways for nonprescription products, 406f
    - criteria for use of, 19, 285
    - evaluation of products, 14
    - flowchart for, 287f
    - for generic products, 381
    - human blood/plasma postmarket pharmacovigilance, 525
    - MAA procedure with, 357f
    - medicinal product registration, 341
    - for medicinal products, 287t
    - multiplication/duplication of applications, 289
    - nonprescription products, 405
    - phases and timeline for medicinal products, 285–287
    - postauthorisation requirements for biotechnology products, 424–425
    - product registration, 356–357
    - Reference Member State selection, 287–288
    - registration for human blood/plasma products, 523
    - registration for medicinal products, 289, 345, 356
    - regulatory dossier assessment, 356–357
    - regulatory information resources for, 554
    - submissions and Reference Member State role and timeline, 286–287
  - Mutual Recognition Regulation*, 502–503, 506
  - mutual recognition/decentralised procedure referral, 293
- N**
- national authorizations, medicinal products, 289
  - national competent authorities, 115–120
    - action on medical device safety, 117–118
    - application for clinical trial authorisation, 320–323
    - clinical trial application, 321t
    - cooperation and coordination for enforcement, 116–117
    - coordination and cooperation enhancement, 117
    - generic medicinal product safety, 390–391
    - inspection process, 366
    - listing of, 562–563t
    - medical devices, 117
    - member states and affiliated countries, 161–163t
    - national regulatory bodies, 116
    - pharmaceutical quality and inspections, 365–369
    - pricing and reimbursement and HTA, 366
    - tissue establishment inspections, 478
  - National Medicines Regulatory Authorities (NMRA), 130
  - National Medicines Verification Organisations

- (NMVOs), 132
- National Procedure
- biosimilar medicinal product registration, 397
  - comparison of pathways for nonprescription products, 406f
  - generic medicinal products, 381
  - human blood/plasma products, 523
  - MAA procedure with, 357f
  - marketing authorisation for medicinal products, 19
  - medical product registration, 345–346
  - medicinal product registration, 357
  - nonprescription medicinal products, 405
  - product registration, 345–346, 356–357
  - regulatory dossier assessment, 357
  - variability of, 285
- new chemical entity (NCE): preclinical test plan, 302
- new legislative framework (NLF) for devices, 157
- nonclinical pharmacodynamics, 235c
- nonclinical studies. *See* Good Laboratory Practice; preclinical testing
- non-invasive devices: classification rules for (*MDR*), 189t
- noninvestigational medicinal products (NIMPs)
- defined, 315
  - SUSARs for, 332
- nonprescription medicinal products, 403–412
- advertising and promotion, 408–409
  - advertising to general public, 409
  - common uses of, 405t
  - definition of, 404
  - herbal medicinal products, 409–410
  - legal basis of MAA, 405
  - legislation of, 404
  - marketing access pathways for, 404–405, 406t
  - pharmacovigilance and safety reporting, 409
  - product information and labelling, 405–407
  - reclassification from prescription to, 407–408
  - role in self-care, 404
  - successful switch strategy for, 408
  - warning statements and guidance for, 407
- Notified Bodies: responsibilities of, 118
- Notified Body Operations Group (NBOG)
- best practices guides, 175t
  - guidance document from, 175, 185–186
- Novel Foods Regulation*, 504
- Nutrition and Health Claims Regulation (NHCR)* (Regulation (EC) No. 1924/2006), 505
- Nutrition Claims (NCs), 505
- O**
- office based evaluation and risk assessment (OBERA), 371
- Official Control Authority Batch Release (OCABR)
- batch-release requirements, 493
  - EDQM procedures for, 522
  - plasma products, 525
- Official Medicines Control Laboratories (OMCL)
- blood/plasma product testing, 522
  - postmarketing lot release, 493
  - vaccine testing by, 490
- operational qualification (OQ), 306
- Opinion, defined, 184
- Oral Explanation (OE) meeting
- purpose of, 55
- Organisation for Economic Co-operation and Development (OECD)
- EMA collaboration, 10
  - GLP guidelines, 327, 375, 390
  - harmonisation of preclinical testing, 302–304
  - mutual acceptance of data system, 370
- Organisational Aspects (ORG) HTA model, 81
- Orphan Drug Act*, 529
- Orphan Medicinal Products (OMP) Regulation*
- COMP established by, 531–532
  - product designation procedure, 535
  - significant benefit concept in, 536–537
  - similar medicinal product and clinical superiority in, 537
- orphan medicinal products (OMPs), 529–542
- annual report requirement, 534
  - application evaluation and timetable for, 533
  - conditional marketing authorisation for, 538
  - designation expiry, 535
  - designation procedure application, 532–533
  - designation request content, 535–536
  - EU laws and regulations, 38
  - European Commission decision, 533–534
  - harmonisation efforts, 530
  - incentives for development, 530–531
  - legal framework, 530
  - MAA for designation product, 536–537, 538
  - medical plausibility for request and prevalence, 536
  - orphan designation benefits, 342
  - orphan designation benefits and criteria, 8, 38, 530, 534f
  - parallel applications, 533
  - pathways for expedited development and approval, 538
  - significant benefit concept in, 536–537
  - similar medicinal product and clinical superiority in, 537
  - sponsorship transfer, 535
- over-the-counter (OTC) medicines. *See* nonprescription medicinal products
- advertising to general public, 108

Own-Brand Labelling (OBL), 146–147

## P

Paediatric Committee (PDCO), 95, 343

Paediatric Investigation Plan (PIP)

Marketing Authorisation Holder, 94–95

submission procedures in, 97–99, 98f

paediatric product regulation

application procedure, 97–99

background and scope, 93–94

compliance check, 99

deferrals, 96–97

Marketing Authorisation Holder, 99–100

PDCO, 95

PIPs, 94–95

population and product definitions, 94

product development under, 100–101

research incentives, 99

waivers, 95–96

*Paediatric Regulation*, 93–94

Paediatric Use Marketing Authorisation (PUMA), 94

Parallel Scientific Advice (PSA), 49

particular nutritional uses (PARNUTs), 512

Patients and Social Aspects (SOC) HTA model, 81

performance qualification (PQ), 306

Periodic Benefit-Risk Evaluation Report (PBRER)

EU format for, 445

format for, 443, 444t

ICH guideline for, 445

Periodic Safety Update Report (PSUR)

benefit-risk balance, 387–388, 401, 425–426, 449

for biosimilar medicinal products, 401

device technical documentation, 227

frequency of, 416

MAH submission of, 443

PMCF in, 261

postmarketing safety assessment, 425, 428, 429

PSUR format revision and scheduling, 445

renewal procedures and, 436

requirements for, 440

RMP update, 447

sharing through Eudamed, 118

submission and review process for, 360

submission of, 443–445

submission to EMA, 353

synchronization with other reports, 333, 426, 445

for technical documentation, 227

validated signals in, 447

Periodic Safety Update Single Assessment (PSUSA)

submission to EMA, 353

*pharmaceutical directives*

ATMPs, 21–22

codification/clarification, 19

development of regulatory system, 20

human-veterinary MAA variations, 20

Pharmaceutical Inspection Convention (PIC), 117, 373

Pharmaceutical Inspection Co-operation Scheme (PIC/S)

for generic products, 379–380

participants in (list), 373–375

pharmacodynamic (PD) testing: biosimilars, 395

pharmacokinetic (PK) testing

for biosimilar medicinal products, 395

with combination product, 235c

pharmacovigilance (PV)

EC definition and development of, 438

fees, 449

GVP overview and modules, 439t

human tissue products, 477–478

ICSR expedited submission requirements, 445f

legal framework, 438–439

notification of withdrawn products, 449

risk management plan modules, 444t

signal management lifecycle, 447f

system master file (PSMF) contents, 441f

vaccines, 493

*Pharmacovigilance Regulation*, 493

Pharmacovigilance Risk Assessment Committee (PRAC)

communications, 56

coordination and cooperation enhancement, 117

MA maintenance, 360

MAA review, 53–54, 54t

photo-safety testing, 303

Plasma Master File (PMF), 280

plasma master file (PMF), 280, 525

Post Market Clinical Follow-up (PMCF), 238

postauthorisation requirements (pharmaceutical)

annual re-assessment

assessment procedures, 431

dossier requirements for, 430–431

for biotechnology-derived products, 424–425

centrally approved product renewal

assessment procedure, 429–430

dossier requirements for, 426

legal framework for, 421, 424–425

major changes/extension application, 435

MRP/DCP product renewal, 424–425

assessment procedures, 426

dossier requirements for, 425

other postauthorisation measures and

enforcement, 431

re-examination, 430

vaccines, 492–493

variations



- assessment/notifications for, 433–435
- dossier requirements for, 431–433
- postauthorisation safety studies (PASS), 324
  - for biosimilar medicinal products, 401
- postmarket clinical follow-up (PMCF)
  - Class III and implantable devices, 238–239, 260–261
  - for clinical efficacy evaluation, 298
  - manufacturer's obligations for, 157
  - use in clinical strategy, 240
- postmarket surveillance (PMS), 260
  - device technical documentation, 227
  - for generic medicinal products, 380
  - manufacturer, 117–118
- postmarket surveillance requirements
  - combination products, 551
- Potential Serious Risk for Public Health (PSRPH)
  - application withdrawal in DCP, 345
- preclinical testing
  - GLP regulations in, 301
  - OECD GLP principles, 303–304
  - See also* Good Laboratory Practice; medical device preclinical testing
- preclinical testing of devices
  - biocompatibility testing, 231, 234c, 235c
  - Design Traceability Matrix for, 231
  - electrical safety and magnetic disturbance testing, 233
  - nonclinical studies, 231, 235
  - packaging validation, 232
  - performance testing, 231
  - preclinical test plan
    - regulatory requirements, 230
    - standards requirements, 230
    - user requirements, 230
  - risk management requirements, 230
  - shelf life (aging) studies, 233
  - software verification and validation, 233
  - statistical methods, 234
  - sterilisation validation, 232–233
  - transport studies, 232
  - usability (human factors) studies, 233
- predicate device
  - GSPRs requirements, 227
- preliminary assessment report (PrAR)
  - Reference Member State (RMS) authoring of, 355–356
- Prescription Medicines Code of Practice Authority (PMCPA), 111
- pricing and reimbursement, 61–76
  - containment policies of Member States, 67f
  - current trends, 67
  - economic evaluations, 66, 66f
  - factors affecting pricing for medicinal products,

- 61–62
- food for special medical purposes (FSMPs), 516
- legal framework, 62–63
- link between models and HTA, 67–74
- models and HTA case studies, 67–74
- models for, 64
  - cost-based pricing, 63–64
  - reference-based, 63, 65t
  - value-based pricing, 64
- pricing factors for, 62f
- reference pricing system for generic products, 377–378
- reimbursement, 65–67
- vaccines, 498
- primary mode of action (PMOA), combination products, 544–545
- PRIME (PRiority MEDicines)
  - HTA/EMA collaboration for, 89
  - laws and regulations, 36–37
- promotion. *See* advertising and promotion

## Q

- Qualified Person (QP/QPPV)
  - generic medicinal products, 389
  - GMP certification, 331
  - for human tissues/ATMPs, 479t
  - pharmacovigilance (PV), 439
  - pharmacovigilance for medicinal products, 280
  - postmarket pharmaceutical compliance, 426–427
  - PSMF and, 387
  - in recall decisions, 119
  - signal management, 446
  - tissue establishment, 479
  - vaccine development, 490
  - vaccine release, 490
  - See also* responsible person (RP)
- Quality Assurance (QA) programme
  - GLP requirements, 305
- Quality Management System (QMS)
  - assessors and inspector relationship in, 364–365, 365f
  - for clinical evaluation procedures, 240
  - in clinical investigation and evaluations, 240
  - in clinical trial protocol, 330
  - for combination products, 550–551
  - in conformity assessment, 248
  - conformity assessment in, 136
  - EU IVDR* requirements, 215
  - human tissue products regulation, 473
  - ICH QMS requirements, 365
  - pharmacovigilance factors for, 440
  - PMS requirements, 118
  - postmarket surveillance in, 117–118, 259

- regulatory strategy for, 138
  - technical documentation for, 226
  - quality review of documents (QRD)
    - labelling templates, 407, 415
    - medicinal product authorisation procedures, 281, 351, 358
    - SmPC information requirements, 388, 448
    - templates in Centralised Procedure, 415
  - quality systems and inspectorate process
    - assessors and inspector relationship in, 365f
    - British Pharmacopoeia (BP)*, 373
    - EDQM inspection process, 369
    - Eurasian Economic Union, 374
    - European Pharmacopoeia (Ph. Eur.)*, 373
    - GCP inspections, 370–371
    - GDP inspections, 371
    - for generic medicinal products, 390
    - GLP inspections, 370
    - GMP inspections, 367–369
    - GMP/GDP Inspectors Working Group, 370
    - ICMRA, 374
    - industry associations, 374
    - for IVDs, 214–215
    - joint inspection program participants, 372–373
    - legal framework for, 366, 366f
    - list of other agency inspections, 371
    - MRAs for inspections, 371
    - OECD, 375
    - pharmaceutical regulation evolution, 363–364
    - pharmacopoeial compendia, 373
    - PIC/S, 373
    - requirements for EU, 365
    - Swiss Pharmacopoeia (Ph. Helv.)*, 373
  - Quality-Adjusted Life Years (QUALYs)
    - in HTA assessment, 84
    - in pricing and reimbursement, 66
- R**
- reference medicine, 377
    - pharmacopoeial compendia for API, 380
  - Reference Member State (RMS)
    - business validation and checklist for, 354
    - DCP role of, 355–356
    - Decentralised Procedure applications role and timeline, 287–288
    - decentralised procedure role, 344
    - follow-up referral, 292
    - initial product assessment, 342
    - MAA evaluation, 19
    - MAA presubmission meetings, 347
    - mutual recognition and decentralised procedure referrals, 293
    - Mutual Recognition Procedure (MRP), 345, 356–357
    - Mutual Recognition Procedure phase 2 timeline, 286
    - Mutual Recognition Procedure role, 286
    - PrAP from, 355
    - renewal date agreement with MAH, 424
    - selection for MAA, 285
    - selection of, 336
    - worksharing for MA maintenance, 359
  - reference-based pricing model, 63, 65t
  - referrals
    - community interest referral, 293
    - divergent decision referral, 293
    - European community referral, 292
    - follow-up referral, 292
    - generic medicinal product evaluation, 381
    - mutual recognition/decentralised procedure referral, 293
  - registration of medicinal products, 341–362
    - accelerated assessment, 347
    - adaptive pathway, 346
    - ASMF for, 350
    - bibliographic applications/well-established use, 349
    - of biosimilar medicinal products, 397–399
    - biosimilar medicinal products, 397–399
    - for biotechnology-derived product, 414–415
    - for biotechnology-derived products, 414–415
    - Certificate(s) of Suitability, 352
    - combination products, 544
    - conditional approval, 346
    - conditional authorisation, 346
    - content of submissions, 351, 351t
    - eCTD envelope and CTD format, 351–352
    - exceptional circumstances, 346–347
    - fixed combination, 349
    - full registration, 348
    - generic products, 391
    - generic registration, 348
    - for human blood or plasma products, 523
    - hybrid registration, 348
    - informed consent, 349
    - MA maintenance, 359–360
    - MAA application types, 347–350
    - MAH liability and, 342
    - materials of human/animal origin, 352
    - mixed marketing, 350
    - orphan medicinal products, 342–343
    - other documentation, 358–359
    - paediatric investigations, 343–344
    - presubmission meeting request, 347
    - procedure types, 344–345
    - PSURs and PSUSAs, 360

- questions on dossier, 358
  - referrals, 360
  - regulatory dossier changes/variations, 359
  - regulatory dossier submission, 352–353
  - regulatory dossier validation, 353–354
  - routes for, 523
  - scientific advice, 343
  - scientific advice application, 350–351
  - similar biological registration, 348–349
  - urgent safety restrictions, 360
  - Regulation defined, 184, 366
  - regulatory authorities
    - Council of Europe, 365
    - EMA, 1–5, 7–10
    - European Commission (EC), 365
    - European Medicines Agency (EMA), 365
    - European Medicines Regulatory Network, 5–7
    - Task Force for Relations with the United Kingdom (UKTF), 364, 366
  - regulatory dossier
    - for blood/plasma products, 524–525
    - Centralised Procedure, medicinal products, 354
    - changes/variations for medicinal products, 359
    - Decentralised Procedure (DCP), medicinal products, 355–356
    - for IVD design, 215
    - Mutual Recognition Procedure (MRP), medicinal products, 356–357
    - National Procedure, medicinal products, 357
    - submission for medicinal products, 352–353
    - validation for medicinal products, 353–354
  - REgulatory FITness and performance programme (REFIT), 502, 506
  - regulatory information resources, 553–574
    - agencies and committees, 557–561
    - association electronic media, 569–570
    - book publishers, 567–568
    - commercial and government databases online, 565–567
    - continued learning and associations, 570
    - core SmPC guidance for vaccines, 496
    - Council of Europe publications on blood/plasma products, 523–524
    - device regulation, 555–556
    - EDQM databases, 567t
    - EMA committees and working parties, 558–559t
    - EU and international organisations, 561–564
    - EU laws and regulations, 556–557
    - framework for medicinal products, human use, 554
    - global regulatory coverage databases, 567–568
    - industry resources in electronic newsletters, 569
    - industry stakeholder organisation, 565t
    - innovative medicines initiative (IMI), 564
    - medical product legislation in Eudralex, 554–555
    - national competent authorities listing, 562–563t
    - professional association/organisations, 564
    - regulators outside the EU, 565
    - regulatory system for medicines, 553–554
    - social networking and mobile apps, 571–572
  - regulatory strategy
    - confirming strategy, 138–139
    - developing and implementing, 136–138
    - documentation of, 138–139
    - information resources for development, 138
    - key questions during development, 137t
    - market considerations in, 135–136
    - prescription to nonprescription strategy, 408
    - review/update of, 139
  - reimbursement. *See* pricing and reimbursement
  - Reporting Member State
    - clinical trial authorisation process, 311, 324–326
    - low-intervention clinical trial determination, 329
  - reprocessing, 147
  - reproductive studies, 303
  - responsible person (RP)
    - generic products, 386
    - tissue quality systems, 478–479, 479t
    - See also* Qualified Person (QP)
  - risk management plan (RMP), 425
    - adaptive pathways and, 346
    - for Advanced Therapy Medicinal Products (ATMPs), 466–467
    - for ATMPs, 466–467
    - biocompatibility testing, 230–231
    - in device industry, 260
    - generic medicinal products, 387
    - pharmacovigilance modules, 444t
    - preclinical device testing, 230
    - requirements for, 440
    - See also* ISO 14971; pharmacovigilance
- ## S
- Safeguard Clause
    - action by Member States, 267
    - action on conforming devices, 117
    - comparison of health monitoring measures, 267–268, 267t
  - Safety (SAF) HTA model, 80
  - safety measures in clinical trials, 323
  - scientific advice and protocol assistance
    - for MAA, 37–38
    - review before EMA meeting, 48
  - Scientific Advice Working Party (SAWP), 37
  - Scientific Advisory Group (SAG) meeting, 55–56
  - scientific committees (EMA)
    - MAA review, 53, 54t

- scientific service implementation, 111
  - serious adverse events (SARs) for IMPs and NIMPs, 332
  - Single European Code (SEC), 476t, 485
  - single-use plastics directive*, 516
  - software
    - EU MDR* and *EU IVDR* reclassification of, 142, 146, 167
    - GSPRs requirements, 222, 231
    - with medical devices, 26, 186, 200–201, 208, 545
    - preclinical device testing, 233
    - verification and validation of, 233, 234c
    - vigilance for, 261
  - somatic cell therapy medicinal products (SCTMPs)
    - clinical development, 465–466
    - intended use and manipulation criteria, 460–461
    - manufacturing process, 462
    - preclinical development, 463–464
  - Spain
    - competent authorities for pricing// reimbursement and HTA, 71
    - HTA in, 82t, 83t
    - National Health Service (SNS), 71
    - pricing/reimbursement procedures, 71–72
  - Spurious/Falsely-Labelled/Falsified/Counterfeit (SFFC) medicines, 121, 126, 129t, 132
  - Standard Assessment Review Timeline
    - EMA meeting preparation, MAA review, 55f
  - Standard Operating Procedures (SOPs), 306
  - Summary of Product Characteristics (SmPC)
    - advertising and promotion compliance, 104–107, 109
    - changes affecting safety, 360, 399–401, 424–425, 432 (*see also* pharmacovigilance)
    - generic and reference products, 33, 379, 382–383
    - human blood or plasma products, 522
      - as IMPD, 331
      - in MAA, 35
    - medicinal product MA maintenance, 279–280, 286–289, 292
    - national competent authority product authorisation, 320
    - product labelling, 388, 407, 427
    - QRD review, 358–359
    - for vaccines, 491, 492, 496
    - See also specific application procedures*
  - Summary of Safety and Clinical Performance (SSCP), 238
  - Summary Technical Documentation (STED), 226–227
  - Supplementary Protection Certificate (SPC)
    - paediatric investigation incentives, 344
    - paediatric medicinal products, 94
    - protection of innovator medicine by, 379
  - supply chain controls: new MDR and IVDD regulation, 142–143
  - suspected unexpected serious adverse reactions (SUSARs)
    - electronic reporting, 318
    - reporting, 332–333
  - Swiss Pharmacopoeia (Ph. Helv.)*
    - quality systems and inspectorate process, 373
- T**
- technical documentation
    - of Essential Requirements compliance, 215
    - EU MDR* and *EU IVDR*, 226–227
    - for IVDs, 215
  - “the garlic case”, 506
  - therapeutic interchangeability
    - biosimilar medicinal products, 22, 399
  - tissue-engineered products (TEPS)
    - clinical development, 466
    - decision tree for classification, 458f
    - intended use and manipulation criteria, 461
    - manufacturing process, 463
    - preclinical development, 465
  - toxicity studies
    - for biosimilar medicinal products, 395
    - preclinical device testing, 235c
    - preclinical testing, 302
  - traceability
    - new regulations, 143–144
    - SEC for tissues/ATMPs, 485
  - Traditional Herbal Medicinal Product Directive (THMPD)*, 409–410, 503, 506
  - traditional herbal medicinal products: regulation evolution, 23
  - Transmissible Spongiform Encephalopathy (TSE)
    - biotechnology-derived products, 417–418
    - blood and plasma evaluation for, 15, 524
  - Transparency Directive*, 17, 62–63, 498, 560
  - Treaty on the Functioning of the EU*, 62
  - trend reporting, 265
- U**
- unique device identifiers (UDI), 138, 143, 215, 268, 485
  - United Kingdom (UK)
    - advertising and promotion, 111–112
    - assessors and inspector relationship in, 364–365
    - Brexit effects for quality management, 364–365
    - Brexit impact on medical devices, 272
    - competent authorities for pricing/reimbursement and HTA, 73

HTA in, 82t, 83t  
 implementation of *ECTR* in, 315  
 National Health Service (NHS), 73  
 pricing/reimbursement procedures, 73–74  
 United States (US): GLP regulations in, 302  
 Urgent Safety Restriction (USR)  
   biosimilar medicinal products, 400  
   dossier requirements for, 426  
   timeframe for implementation, 432–433  
   variation classification and, 436  
 usability testing, 234c

## V

vaccine adverse event reporting system (VAERS), 493  
 Vaccine Antigen Master File (VAMF)  
   development processes for, 491, 492  
   EU regulations, 21  
   veterinary vaccines, 23  
 vaccines, 489–500  
   adjuvants in, 496–497  
   classification and development pathway, 489–490  
   clinical studies, 492  
   CTA for, 490–491  
   DNA and therapeutic vaccines/GMO-based, 497–498  
   GMO-based vaccines, 497–498  
   guidance on, 496  
   immunomodulators in, 497  
   licensure, 492–498  
   lot release, 492  
   manufacturing process, 490–491  
   nonclinical studies, 491–492  
   overview, 498  
   pandemic influenza, 496  
   pharmacovigilance (PV), 493  
   prepandemic influenza vaccines, 496  
   pricing and reimbursement, 498  
   seasonal influenza vaccines, 494–495, 495f  
   for special populations, 494  
   vaccines, 492–493  
   VAMF, 491  
   VAMF certification, 491t  
   VAMF certification and requirements, 21  
   vector use in, 497  
 value-based pricing model, 64  
 veterinary medicinal products  
   CMDv, 18  
   CVMP role in authorisation, 8  
   GMP inspections for, 373–374  
   national competent authorities for, 6–7  
   OMCLs testing, 522

pharmaceutical regulation evolution, 22–23  
 regulatory agencies for, 2–3, 4–5, 365–366  
 regulatory principles, 22–23  
 scientific advice and protocol assistance, 48  
 variations to MAAs, 20–21  
*See also specific application procedures*  
 vigilance procedures for IVDs, 214–215  
 viral clearance, 418  
 Voluntary Harmonisation Procedure (VHP)  
   CTFG and, 336  
   implementation and guidance for, 313

## W

worksharing in market authorisation maintenance, 359  
 World Health Organization (WHO)  
   falsified medicine initiative/IMPACT, 122, 564  
   generic medicinal product definition, 377  
   Global Surveillance and Monitoring System (GSMS), 130  
   HTA definition by, 66  
   International Clinical Trials Registry Platform (WHO ICTRP), 335  
   paediatric medicine initiative, 100  
   pandemic vaccine development and, 496  
   wrongly affixed CE-marking, 117